<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171951</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230B2208E1</org_study_id>
    <secondary_id>2004-002407-32</secondary_id>
    <nct_id>NCT00171951</nct_id>
  </id_info>
  <brief_title>Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease</brief_title>
  <official_title>Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic
      hormone (ACTH) secreting pituitary adenoma. This study will assess the long-term safety and
      efficacy of pasireotide in patients with Cushing's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term efficacy (UFC) in patients with Cushing's disease</measure>
    <time_frame>at the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term safety</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of biomarker</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cushing Disease</condition>
  <arm_group>
    <arm_group_label>Pasireotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide</intervention_name>
    <arm_group_label>Pasireotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have completed the 15 days of Pasireotide treatment in the CSOM230B2208
             study and have achieved normalization of 24-hour urinary free cortisol. Patients who
             did not achieve normalization of 24 -hour urinary free cortisol may be enrolled if in
             the opinion of the investigator the patient is getting significant clinical benefits
             from treatment with Pasireotide .

          -  The patient did not experience any unacceptable adverse events of tolerability issues
             during the original 15 day treatment.

          -  Female patients of child bearing potential who have not undergone clinically
             documented total hysterectomy and/or ovariectomy, or tubal ligation must agree to use
             barrier contraception throughout the course of the extension study, and for one month
             after the study has ended

        Exclusion Criteria:

          -  Patients who have developed poorly controlled diabetes mellitus as indicated by
             ketoacidosis or HgbA1C &gt; 10 since starting [study CSOM230B2208]

          -  Patients with persistent ALT/AST or alkaline phosphatase levels more than 2.5X ULN,
             serum creatinine &gt; 2.0 X ULN, serum bilirubin &gt; 2 X ULN

          -  Patients with abnormal coagulation (PT and PTT elevated by 30% above normal limits),
             WBC &lt;3.0x1'000'000'000/L; Hgb &lt;12.0g/dL for females, Hgb &lt;13.0g/dL for males; PLT
             &lt;100x1'000'000'000/L

        Other protocol-defined inclusion / exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticlas</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University Dept.ofOregonHealth&amp;SciencesU.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=11523</url>
    <description>Results for CSOM230B2208E1 from the Novartis Clinical Trials Website</description>
  </link>
  <results_reference>
    <citation>Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BM. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study. Pituitary. 2014 Aug;17(4):320-6. doi: 10.1007/s11102-013-0503-3.</citation>
    <PMID>23943009</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cushing's disease</keyword>
  <keyword>ACTH</keyword>
  <keyword>Cortisol</keyword>
  <keyword>ACTH dependent Cushing's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

